Translating the regulatory landscape of medical devices to create fit‐for‐purpose artificial intelligence (AI) cytometry solutions
- 23 February 2024
- journal article
- review article
- Published by Wiley in Cytometry Part B: Clinical Cytometry
- Vol. 106 (4) , 294-307
Abstract
The implementation of medical software and artificial intelligence (AI) algorithms into routine clinical cytometry diagnostic practice requires a thorough understanding of regulatory requirements and challenges throughout the cytometry software product lifecycle. To provide cytometry software developers, computational scientists, researchers, industry professionals, and diagnostic physicians/pathologists with an introduction to European Union (EU) and United States (US) regulatory frameworks. Informed by community feedback and needs assessment established during two international cytometry workshops, this article provides an overview of regulatory landscapes as they pertain to the application of AI, AI‐enabled medical devices, and Software as a Medical Device in diagnostic flow cytometry. Evolving regulatory frameworks are discussed, and specific examples regarding cytometry instruments, analysis software and clinical flow cytometry in‐vitro diagnostic assays are provided. An important consideration for cytometry software development is the modular approach. As such, modules can be segregated and treated as independent components based on the medical purpose and risk and become subjected to a range of context‐dependent compliance and regulatory requirements throughout their life cycle. Knowledge of regulatory and compliance requirements enhances the communication and collaboration between developers, researchers, end‐users and regulators. This connection is essential to translate scientific innovation into diagnostic practice and to continue to shape the development and revision of new policies, standards, and approaches.Keywords
This publication has 21 references indexed in Scilit:
- Artificial intelligence innovation in healthcare: Literature review, exploratory analysis, and future researchTechnology in Society, 2023
- Algorithmic fairness in artificial intelligence for medicine and healthcareNature Biomedical Engineering, 2023
- The regulatory landscape of laboratory developed tests: Past, present, and a perspective on the futureJournal of Mass Spectrometry and Advances in the Clinical Lab, 2023
- Computational pathology in 2030: a Delphi study forecasting the role of AI in pathology within the next decadeEBioMedicine, 2023
- A unifying force for the realization of medical AInpj Digital Medicine, 2022
- Artificial intelligence in anatomical pathology: building a strong foundation for precision medicineHuman Pathology, 2022
- Laboratory-Developed Tests: Design of a Regulatory Strategy in Compliance with the International State-of-the-Art and the Regulation (EU) 2017/746 (EU IVDR [In Vitro Diagnostic Medical Device Regulation])Therapeutic Innovation & Regulatory Science, 2021
- How artificial intelligence might disrupt diagnostics in hematology in the near futureOncogene, 2021
- The regulatory landscape of precision oncology laboratory medicine in the United States – Perspective on the past 5 years and considerations for future regulationPractical Laboratory Medicine, 2020
- An overview of clinical decision support systems: benefits, risks, and strategies for successnpj Digital Medicine, 2020